Heart stent patients: which blood thinner combo is safer?

NCT ID NCT05681702

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at two strategies to reduce bleeding in people with coronary artery disease who have had a stent placed and are on blood thinners. One approach is to switch from a stronger blood thinner to a milder one while keeping aspirin. The other is to stop aspirin and stay on the stronger blood thinner alone. The trial will measure how well each strategy prevents blood clots in a lab test, involving 90 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aspirin plus clopidogrel, or prasugrel or ticagrelor alone
What this could lead to: If successful, this study could help doctors choose the best strategy to reduce bleeding risk while still preventing heart attacks in patients who have had a stent placed.
What could go wrong: This is a small, early-phase study (90 participants) measuring blood clotting in a lab, not actual heart attacks or bleeding events. Results may not translate to real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

University of Florida
RECRUITING

Jacksonville, Florida, 32209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.